ISIS 416858 + Placebo
Phase 2Completed 3 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
End-stage Renal Disease (ESRD)
Conditions
End-stage Renal Disease (ESRD)
Trial Timeline
Oct 1, 2015 → Nov 1, 2016
NCT ID
NCT02553889About ISIS 416858 + Placebo
ISIS 416858 + Placebo is a phase 2 stage product being developed by Bayer for End-stage Renal Disease (ESRD). The current trial status is completed. This product is registered under clinical trial identifier NCT02553889. Target conditions include End-stage Renal Disease (ESRD).
What happened to similar drugs?
8 of 9 similar drugs in End-stage Renal Disease (ESRD) were approved
Approved (8) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03358030 | Phase 2 | Completed |
| NCT02553889 | Phase 2 | Completed |
Competing Products
20 competing products in End-stage Renal Disease (ESRD)